Author:
Wang Dan,Yuan Jiajia,Liu Hong-Li,Li Shi-lian,Ma Nan,Chen Meng-lan,Yuan Hua,Jie Hong,Li Bin,Zhang Tao
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Lam BL, Feuer WJ, Schiffman JC, Porciatti V, Vandenbroucke R, Rosa PR, Gregori G, Guy J. Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy : preparation for gene therapy clinical trial. JAMA Ophthalmol. 2014;132:428–36.
2. Coussa RG, Merat P, Levin LA. Propagation and selectivity of axonal loss in Leber hereditary optic neuropathy. Sci Rep. 2019;9:6720.
3. Spruijt L, Kolbach DN, de Coo RF, Plomp AS, Bauer NJ, Smeets HJ, de Die-Smulders CE. Influence of mutation type on clinical expression of Leber hereditary optic neuropathy. Am J Ophthalmol. 2006;141:676–82.
4. Stone EM, Newman NJ, Miller NR, Johns DR, Lott MT, Wallace DC. Visual recovery in patients with Leber’s hereditary optic neuropathy and the 11778 mutation. J Clin Neuroophthalmol. 1992;12:10–4.
5. Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, Atawan A, Chattopadhyay S, Schubert M, Garip A, et al. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain. 2011;134:2677–86.